1

An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with <sup>18</sup>F-PM-PBB3 (<sup>18</sup>F-APN-1607)

4

# 5 AUTHORS/AFFILIATIONS:

Kenji Tagai<sup>1,2,5\*</sup>, Yoko Ikoma<sup>1,5</sup>, Hironobu Endo<sup>1</sup>, Oiendrila Bhowmik Debnath<sup>1</sup>, Chie 6 Seki<sup>1</sup>, Kiwamu Matsuoka<sup>1</sup>, Hideki Matsumoto<sup>1</sup>, Masaki Oya<sup>1</sup>, Kosei Hirata<sup>1</sup>, Hitoshi  $\overline{7}$ Shinotoh<sup>1</sup>, Keisuke Takahata<sup>1,3</sup>, Shin Kurose<sup>1,3</sup>, Yasunori Sano<sup>1,3</sup>, Maiko Ono<sup>1</sup>, Hitoshi 8 Shimada<sup>1,4</sup>, Kazunori Kawamura<sup>1</sup>, Ming-Rong Zhang<sup>1</sup>, Yuhei Takado<sup>1\*</sup>, Makoto Higuchi<sup>1</sup> 9 10 <sup>1</sup> Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, 11 National Institutes for Quantum and Radiological Science and Technology, Chiba 263-128555, Japan 13<sup>2</sup> Department of Psychiatry, The Jikei University of Medicine, Tokyo 105-8461, Japan 14<sup>3</sup> Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016, Japan 1516<sup>4</sup> Department of Functional Neurology & Neurosurgery, Center for Integrated Human Brain Science, Brain Research Institute, Niigata University, Niigata 951-8585, Japan 17<sup>5</sup> These authors contributed equally 18\* Correspondence: tagai.kenji@qst.go.jp, takado.yuhei@qst.go.jp 19 20212223

24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 1 ABSTRACT

Positron emission tomography (PET) with <sup>18</sup>F-PM-PBB3 (<sup>18</sup>F-APN-1607) enables high- $\mathbf{2}$ contrast detection of tau depositions in various neurodegenerative dementias, including 3 Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD). A simplified 4 method for quantifying the radioligand binding in target regions is to employ the  $\mathbf{5}$ cerebellum as a reference (CB-ref) on the assumption that the cerebellum has minimal 6 tau pathologies. This procedure could be valid in AD, while FTLD disorders exemplified 7progressive supranuclear palsy (PSP) are characterized by occasional tau 8 bv 9 accumulations in the cerebellum, hampering the application of CB-ref. The present study 10 aimed to establish an optimal method for defining reference tissues on <sup>18</sup>F-PM-PBB3-PET images of the AD and non-AD tauopathy brains. We developed a new algorithm to 11 12extract reference voxels with a low likelihood of containing tau deposits from gray matter (GM-ref) or white matter (WM-ref) by a bimodal fit to an individual, voxel-wise 13histogram of the radioligand retentions and applied it to <sup>18</sup>F-PM-PBB3-PET data obtained 14from age-matched 40 healthy controls (HCs) and 23 AD, 40 PSP, and five other tau-1516positive FTLD patients. PET images acquired at 90-110 min after injection were averaged and co-registered to corresponding magnetic resonance imaging space. Subsequently, we 1718generated standardized uptake value ratio (SUVR) images estimated by CB-ref, GM-ref 19and WM-ref respectively, and then compared the diagnostic performances. GM-ref and WM-ref covered a broad area in HCs and free of voxels located in regions known to bear 20high tau burdens in AD and PSP patients. GM-ref allowed the most robust separation of 21AD and PSP patients from HCs according to the area under the curves in receiver 2223operating characteristic curve analyses. GM-ref also provided SUVR images with higher 24contrast than CB-ref in FTLD patients with suspected and confirmed corticobasal

1	degeneration. The methodology for determining reference tissues as optimized here				
2	reinforces the accuracy of <sup>18</sup> F-PM-PBB3-PET measurements of tau burdens in a wide				
3	range of neurodegenerative illnesses.				
4					
5	KEY WORDS:	tau PET, reference tissues, Alzheimer's disease, progressive			
6		supranuclear palsy, frontotemporal lobar degeneration			
7					
8					
9					
10					
11					
12					
13					
14					
15					
16					
17					
18					
19					
20					
21					
22					
23					
24					

# 1 1. Introduction

Depositions of tau fibrils in the brain are the hallmarks of Alzheimer's disease (AD) and a significant subset of frontotemporal lobar degeneration (FTLD), including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Pick's disease (PiD). The structures of tau in these and diverse other tauopathies are distinct (1, 2) and determine the subcellular, cellular, and regional distribution of tau aggregates in close relationships with clinical phenotypes (3, 4).

The recent development of radioligands for positron emission tomography (PET) has 8 9 enabled *in vivo* visualization of tau fibril depositions (5, 6). To quantify tau accumulations 10 in the AD brains, a ratio of the radioactivity uptake between target and reference tissue defined as standardized uptake value ratio (SUVR) or distribution volume ratio is often 11 employed as a simplified index for the specific probe binding to tau aggregates under the 12assumption that the reference region is devoid of tau lesions harboring binding 13components. Similarly, time-radioactivity curves in the target and reference regions are 14comparatively utilized for the estimation of non-displaceable binding potential (BP<sub>ND</sub>) of 1516 the radiotracer according to pharmacokinetic models. The reference tissue is primarily defined on the cerebellar gray matter (CB-ref) for PET measurements of AD-type tau 17pathologies since this anatomical structure is supposed to contain minimal tau fibrils in 1819AD (7-10).

While most PET probes for tau deposits are incapable of sensitive detection of FTLDtype tau assemblies formed by a subgroup of tau isoforms, we developed a PET ligand, <sup>11</sup>C-PBB3, for visualizing AD and non-AD tau pathologies, including PSP-, CBD-, and PiD-type tau inclusions (11). <sup>11</sup>C-PBB3 did not yield abundant radiosignals in the brain due to its high propensity to metabolic conversions and consequent inefficiency of its

transfer to the brain, but a fluorinated analog of <sup>11</sup>C-PBB3, <sup>18</sup>F-PM-PBB3 (also known as 1  $\mathbf{2}$ <sup>18</sup>F-APN-1607), displayed improved biostability and allowed detection of a wide range of tau lesions with high contrast (12). The use of CB-ref might lead to underestimation of 3 the radiotracer binding in target tissues, particularly in patients with PSP and CBD, as tau 4 pathologies could exist in the cerebellum of these cases (13, 14). To circumvent this  $\mathbf{5}$ technical issue, we extracted reference voxels with a low likelihood of tau depositions 6 from gray matter in parametric images based on whether the voxel-wise BP<sub>ND</sub> was within 7a range assigned using a histogram in healthy controls (13). This method was applied to 8 determining BP<sub>ND</sub> of <sup>11</sup>C-PBB3 in subjects with AD (13), PSP (14), and several other 9 10 non-AD tauopathies (15, 16). More recently, other research groups constituted a procedure to extract reference voxels from white matter based on whether the voxel-wise 11 radiotracer retention was included in a range assigned using an individual histogram (17, 1218). This methodology was then implemented in the estimation of <sup>18</sup>F-PM-PBB3 13retention in AD cases (18), and the employment of individual histograms allowed handy 14quantitative assays without generating an average histogram in control subjects. However, 1516it remains unclear whether reference voxels should be collected from gray or whiter matter, and how the range of the probe retention in the histogram is selected for the 1718reference extraction also needs to be determined.

The present study aims to establish an optimal method to define reference voxels for the quantification of <sup>18</sup>F-PM-PBB3 binding in diverse tauopathies. We constructed a new workflow to assign the range of the probe uptake for picking up adequate voxels with sufficient robustness in consideration of diverse histogram profiles. Then, the accuracy of diagnostic discriminations and contrasts for tau pathologies were compared among CBref and pools of reference voxels extracted from gray matter (GM-ref) and white matter

1 (WM-ref).

 $\mathbf{2}$ 

#### 3 2. Methods

4

#### 5 2.1. Participants

We analyzed age-matched datasets of 40 healthy controls (HCs), 23 patients with AD, 6 40 patients with PSP, and five patients with other FTLD syndromes. These datasets were 7acquired from clinical studies registered in UMIN Clinical Trials Registry (UMIN-CTR; 8 9 IDs 000030248, 000034546, 000033808, and 000030319). They were approved by the 10 Radiation Drug Safety Committee and National Institutes for Quantum Science and Technology Certified Review Board of Japan. Written informed consent was obtained 11 12from all subjects and/or from close family members when subjects were cognitively impaired. 13

14All patients were clinically diagnosed according to the established criteria as we previously reported (19-24). Depositions of amyloid-beta (A $\beta$ ) were assessed by a visual 1516inspection of <sup>11</sup>C-PiB-PET images (12). All AD patients were indicated by PET to have A  $\beta$  plaques and denoted as A  $\beta$  (+), and five A  $\beta$  (+) MCI patients were added to the AD 17group. The PSP group consisted of 33 patients with PSP Richardson syndrome (PSP-1819Richardson) with typical manifestations and seven patients with other clinical phenotypes (PSP-other). HCs were without a history of neurological and psychiatric disorders, and 20they were age-matched with the AD and PSP groups (Table 1). Patients with other FTLDs, 21including corticobasal degeneration syndrome (CBS), progressive non-fluent aphasia 2223(PNFA), and behavioral variant of frontotemporal dementia (BvFTD), were also 24incorporated as in our previous report (12), and two of these cases were

neuropathologically diagnosed as having CBD and PiD by biopsy and autopsy,
 respectively (25). All HCs, PSP, and other FTLD patients were Aβ(-) according to PET
 findings.

4

# 5 2.2. Image acquisition and data preprocessing

6 MR images were acquired with a 3-T scanner, MAGNETOM Verio (Siemens Healthcare). Three-dimensional T1-weighted gradient-echo sequence produced a gapless  $\overline{7}$ series of thin sagittal sections (TE = 1.95 ms, TR = 2300 ms, TI = 900 ms, flip angle = 8 9 9°, acquisition matrix =  $512 \times 512 \times 176$ , voxel size =  $1 \times 0.488 \times 0.488$  mm). PET assays 10 were conducted with a Biograph mCT Flow system (Siemens Healthcare), which provides 109 sections with an axial field of view of 16.2 cm. The intrinsic spatial 11 12resolution was 5.9 mm in-plane and 5.5 mm full-width at half-maximum axially. Images 13were reconstructed using a filtered back-projection algorithm with a Hanning filter (4.0 mm full-width at half-maximum). <sup>18</sup>F-PM-PBB3 were injected into the subjects with an 14average dose of  $186.4 \pm 8.2$  MBq and a molar activity of  $237.4 \pm 75.3$  GBq/µmol. 15

16 Data preprocessing was performed using PMOD 3.8 (PMOD Technologies Ltd) and Statistical Parametric Mapping software (SPM12, Wellcome Department of Cognitive 17Neurology). Acquired PET images were corrected for head motions and then rigidly co-18 registered to individual T1-weighted MR images. To generate standardized uptake value 19ratio (SUVR) images, we averaged PET data acquired at 90 - 110 min after radiotracer 20injection. In addition, the individual MR images were segmented, and the probability 2122maps of gray matter (GM) and white matter (WM) were generated using SPM12 for the 23extraction of reference voxels based on histogram analysis.

#### 1 2.3. Histogram-based definition of reference voxels

 $\mathbf{2}$ 

We propose a new method to define reference voxels in GM or WM based on the 3 frequency histogram of voxel-counts with a homemade script implemented MATLAB 4 (The Mathworks, Natick, MA, USA). A binary mask image of GM or WM was generated  $\mathbf{5}$ from the probability maps by selecting voxels with a higher than 90% probability of being 6 GM or WM. The erosion with morphological operation using 3 x 3 x 3 neighboring voxels  $\overline{7}$ was also conducted on each mask to eliminate influence from the boundary regions. 8 9 Subsequently, a voxel-wise frequency histogram of voxel-counts was constructed from 10 an individual PET image masked for GM or WM.

A bimodal Gaussian distribution fit was then applied to the histogram in light of the view 11 that voxels with and without tau pathologies formed two distinct peaks. The first Gaussian 12distribution with the lower-count peak was regarded to contain voxels with no or minimal 1314tau deposits, and hence voxels with values within the full-width at half-maximum (FWHM) of this peak were extracted and pooled as a reference region. Tracer retention 1516in the extracted reference region  $(C_{ref})$  was determined by averaging reference voxel values weighted for the probability of being contained in the first versus second Gaussian 1718distribution (*w*<sub>i</sub>) as follows:

19 
$$C_{ref} = \sum_{i=1}^{N} w_i C_i / \sum_{i=1}^{N} w_i$$

20 
$$w_i = g_1(C_i) / (g_1(C_i) + g_2(C_i)),$$

where  $C_i$  is the value of the i'th voxel,  $g_1$  and  $g_2$  are the first and second Gaussian distribution functions, respectively, and *N* is the number of reference voxels (Figure 1A). If the height of the first peak was less than half of the second peak, we applied

monomodal Gaussian distribution to the histogram to circumvent potential lack of the 1 fitting robustness in the bimodal fit due to an insufficient number of voxels in the first  $\mathbf{2}$ peak (Figure 1B). The monomodal Gaussian distribution fit was then evaluated by the 3 Dice coefficient, which is a ratio of the area between the doubled intersection of the 4 polygonized histogram and fitted Gaussian distribution and the sum of these two polygons.  $\mathbf{5}$ 6 If the Dice coefficient was smaller than the threshold value determined with HC data in the current cohort, the bimodal Gaussian distribution fit was considered more appropriate  $\overline{7}$ than the monomodal fit (Figure 1C). The threshold was set at 0.936, which is the mean -8 9 2 standard deviation (SD) value of cases in which monomodal fitting was applied in HCs. 10 In the use of the monomodal fit,  $C_{ref}$  was determined by averaging counts in all voxels within the FWHM (Figure 1B). Finally, all voxel-counts were normalized by  $C_{ref}$  in GM-11 ref or WM-ref as well as retention in CB-ref (cerebellar cortex) labeled with Freesurfer 126.0 from the Desikan-Killiany-Tourville atlas as a conventional method (25), to produce 1314SUVR images, respectively.

15

16 2.4. Target regions

17

The target region was placed at an area with abundant tracer binding in AD and PSP patients, according to our previous studies (12). We defined volumes of interest (VOIs) in the neocortex involved in AD tau pathologies at the Braak stages V and VI (BraakV/VI) and in the subthalamic nucleus (STN) burdened with PSP-type tau deposits. The Braak V/VI VOI was labeled using FreeSurfer 6.0 as described elsewhere. The STN VOI was defined with a template atlas (Talairach Daemon atlas from the Wake Forest University PickAtlas version 3.0.5) in the MNI (Montreal Neurologic Institute) space, and spatial

normalization was conducted according to the Diffeomorphic Anatomical Registration
Through Exponentiated Lie Algebra (DARTEL) algorithm. For other FTLDs, VOIs were
also generated with FreeSurfer 6.0 in areas enriched with tau lesions characteristic of each
disease, such as the precentral cortex in CBS and PNFA and the orbitofrontal cortex in
BvFTD.

6

## 7 2.5. Statistical analyses

Statistical examinations were performed using GraphPad Prism 9.0. We adapted Fisher's 8 9 exact test (sex) and Kruskal-Wallis test (other parameters) for comparisons between HCs, 10 AD, and PSP groups (P < 0.05, corrected for Dunn's multiple comparisons). The performance of the diagnosis based on SUVR values in the target VOIs against CB-ref, 11 12GM-ref, and WM-ref was evaluated using Mann-Whitney U test and area under the curve (AUC) values in Receiver Operating Characteristic (ROC) curves. Subsequently, linear 1314regression analysis was conducted to assess correlations between SUVRs estimated with these three reference tissues. 15

16

17	3.	Results

18

# 19 *3.1. Evaluations of reference tissues*

20

Table 1 shows the demography of the subjects and volumes of defined CB-ref, GM-ref, and WM-ref. The bimodal Gaussian distribution fit to the histogram was judged as adequate in most cases, while the monomodal fit was chosen in GM histograms of six HCs and five PSP, and WM histograms of one HC and one AD case. Figure 2

1	demonstrates representative images of GM-ref and WM-ref. As a result of Gaussian
2	fitting, voxels in GM-ref showed a tendency to pick up from the entire cortex in HCs, the
3	cerebellum in AD, and regions excluding the cerebellum in PSP cases. Meanwhile, voxels
4	in WM-ref were extracted from the entire WM in HCs and AD and regions excluding a
5	WM portion of the basal ganglia in PSP.
6	
7	3.2. Diagnostic performance of quantifications with CB-ref, GM-ref, and WM-ref
8	
9	Figure 3 illustrates comparisons of SUVRs in the target VOIs among the AD, PSP, and
10	HC groups and ROC curve analyses for the discrimination of AD or PSP patients from
11	HCs. SUVRs determined with all three reference tissues exhibited significant differences
12	between the patient and HC groups ( $p < 0.05$ , Figure 3A, B), whereas the SD of these
13	values estimated with WM-ref was higher than those estimated with CB-ref and GM-ref
14	in HCs (Supplemental Table 1).
15	In ROC curve analyses, the use of CB-ref and GM-ref yielded high AUC values (=
16	0.998) relative to WM-ref (= 0.985) in the separation between AD patients and HCs
17	(Figure 3C). GM-ref also produced a higher AUC value (= 0.930) than WM-ref (= 0.923)
18	and CB-ref (= 0.918) in the discrimination between PSP patients and HCs (Figure 3C).
19	
20	3.3. Comparisons of imaging data yielded by CB-ref and GM-ref
21	
22	We then compared parametric SUVR images generated with CB-ref and GM-ref as these
23	reference tissues enabled better differentiation between the patients and HCs than WM-
24	ref. The analyses with CB-ref and GM-ref similarly captured spreading of the tracer

retention from the medial and inferior temporal regions to the other neocortical areas 1  $\mathbf{2}$ along with cognitive declines in the continuum from MCI to AD (Figure 4A). Moreover, SUVRs in the target VOIs estimated with GM-ref and CB-ref were in good agreement 3 with each other in MCI and AD cases (Figure 4B). By contrast, the quantification using 4 GM-ref detected tau depositions in PSP patients with higher SUVR than the analysis with  $\mathbf{5}$ CB-ref (Figure 5A). Notably, tau accumulations primarily in the midbrain and left 6 neocortical areas were undetectable with CB-ref but were clearly visualized with GM-ref  $\overline{7}$ in a PSP patient with aphasia (PSP-SL) (Figure 5A). GM-ref yielded higher SUVR values 8 9 in the target VOIs than CB-ref in these PSP cases, indicating high contrast for tau 10 aggregates provided by GM-ref (Figure 5B).

We also assessed individual SUVR images of patients with various clinical and/or 11 neuropathological phenotypes of non-PSP FTLDs (Figure 6). In a case with 12neuropathologically confirmed CBD, the assay with GM-ref captured tau depositions in 1314the motor cortex and subcortical areas more sensitively than the use of CB-ref. Besides, GM-ref allowed imaging of tau pathologies with topologies characteristic of PSP and 1516 CBD in Non-AD CBS and PNFA patients with higher contrast than CB-ref. Finally, SUVR images generated with CB-ref and GM-ref displayed high similarity in BvFTD 1718patients with suspected or confirmed PiD neuropathology, presumably due to the lack of 19tau aggregates in the cerebellum.

20

# 21 **4. Discussion**

In the present work, we have optimized the determination of reference tissue for the sensitive and precise PET detection of tau pathologies in various neurodegenerative dementias. This methodology reinforces the advantage of <sup>18</sup>F-PM-PBB3 as an imaging

agent for AD and non-AD tau depositions. In addition to the conventional CB-ref 1 placement, Gaussian fits to individual histograms of <sup>18</sup>F-PM-PBB3 retentions in GM and  $\mathbf{2}$ WM segments provided a range of radioligand uptakes for the extraction of voxels with 3 a low likelihood of possessing tau deposits. Notably, GM-ref performed as accurately as 4 CB-ref and better than WM-ref in the discrimination between AD-spectrum cases and  $\mathbf{5}$ HCs and enabled more robust differentiation of PSP patients from HCs than did CB-ref 6 and WM-ref. Accordingly, our findings rationalize the utilization of GM-ref for capturing  $\overline{7}$ and quantifying different types of tau accumulations in any of the brain regions, including 8 9 the cerebellum.

10 The application of histograms enabled us to exclude regions that were likely to contain specific binding and to extract optimized reference regions regardless of the type of 11 diseases (13, 17). A vital issue in the histogram-based definition of reference voxels is the 12choice of an adequate mathematical model to describe the observed curves, as 1314exemplified by monomodal and bimodal Gaussian fits. In the employment of our precedent tau PET probe, <sup>11</sup>C-PBB3, a relatively low dynamic range for the detection of 1516specific binding components impeded the application of a bimodal fit to the acquired image data (11, 13). By contrast, high contrasts for tau deposits produced by <sup>18</sup>F-PM-1718PBB3 have allowed clear separation between two histogram clusters representing voxels 19with and without noticeable tau pathologies and voxels lacking PET-visible tau fibrils constitute the first, larger peak (Fig. 1A). Meanwhile, the two peaks can be barely 20discriminated in histograms of HCs burdened with few tau aggregates and PSP cases 21harboring low-grade tau depositions, justifying the use of a monomodal fit in these 2223subjects (Fig. 1B). Moreover, the first peak may be small but distinguishable from the 24second peak in patients with advanced AD, and GM-ref extracted by the bimodal fitting

1 resembled CB-ref (Fig. 1C).

An additional advantage of the current procedure over the previous method (13) is the assignment of a radioligand uptake range for the selection of reference voxels in each individual without introducing average cutoff values determined in the HC group. The group-wise cutoff could vary in a manner dependent on PET scanners and image reconstruction algorithms, precluding the unification of tau measurements among different PET facilities. The circumvention of this drawback in the present workflow will therefore facilitate multicenter tau PET assessments of elderly subjects on a large scale.

9 In this study, GM-ref yielded higher AUC values in the ROC analysis than WM-ref 10 across the diseases, which was primarily attributed to the variability in the quantification of SUVRs with WM-ref in HCs. WM-ref had been reported to be valid in several amyloid 11 and tau PET studies (17, 26, 27) as its large size could be advantageous for reducing the 12statistical variability relative to CB-ref. In the meantime, non-specific retentions of these 1314radioprobes in WM areas have been observed to vary among HCs partially in relation to aging (28, 29). It is also noteworthy that even slight alterations of off-target tracer binding 1516may lead to large variabilities of SUVRs in the use of WM-ref if the background (free) tracer retention in WM is very low. Although factors affecting the non-displaceable 17uptake of <sup>18</sup>F-PM-PBB3 in WM are yet to be identified, we consider GM-ref to be 1819preferable to WM-ref for the quantification of tau deposits with this radioligand.

GM-ref also exhibited better diagnostic performance than CB-ref in patients with FTLD disorders, particularly in those with putative and confirmed PSP and CBD pathologies. Indeed, PSP tau pathologies could involve the cerebellar dentate nucleus and adjacent WM from a relatively early stage (30, 31). Similarly, tau lesions can be found in these areas of atypical or advanced CBD cases (32-34). Furthermore, tau inclusions in

cerebellar GM Purkinje cells have also been detected in both PSP and CBD patients (35, 1  $\mathbf{2}$ 36). Thus, the localization of these pathological tau aggregates could undermine the 3 validity of CB-ref for the PET assessment of FTLD disorders. The histogram-based reference definition proposed here can exclude voxels with potential tau pathologies 4 throughout the entire GM or WM, including the cerebellar regions, in an unbiased fashion.  $\mathbf{5}$ 6 In fact, GM-ref was composed of extensive neocortical areas rather than the cerebellar sectors in consecutive PSP and CBD cases, along with CBS and PNFA patients suspected  $\overline{7}$ of having PSP or CBD pathologies, and low-grade tau accumulations in neocortical 8 9 structures of these subjects could be captured by using GM-ref but not CB-ref. By contrast, 10 tau depositions in PiD patients were nearly equally detectable by applying GM-ref and CB-ref, in agreement with the lack of intense cerebellar tau lesions in this disorder. 11

As mentioned above, GM-ref and CB-ref showed comparable diagnostic performance in discriminating AD cases from HCs. We also postulate that GM-ref can utilize a larger volume of brain areas than CB-ref in the assays of patients with prodromal and early AD, contributing to a gain of the quantification stability. This potential benefit would help sensitive detection of tau accumulations with low abundances in incipient AD.

In conclusion, the newly developed workflow for the determination of reference tissue fortifies the utility of <sup>18</sup>F-PM-PBB3 for investigating a broad spectrum of neurodegenerative tauopathies with high contrast. The tau PET technology in conjunction with this quantitative procedure will also permit longitudinal measurements of tau aggregates with minimal influences of temporal changes in specific and non-displaceable binding components at a certain location, which is advantageous in the evaluation of emerging anti-tau therapeutics for AD and FTLD disorders.

24

## 1 Funding

This study was supported in part by AMED under Grant Number JP18dm0207018, JP19dm0207072, JP18dk0207026, JP19dk0207049, and by MEXT KAKENHI Grant Number JP16H05324, JP18K07543, by JST CREST Grant Number JPMJCR1652 and by Biogen Idec Inc. and APRINOIA Therapeutics.

6

#### 7 Data accessibility

8 Requests for data that support the findings of this study should be directed to 9 Correspondence, Kenji Tagai (tagai.kenji@qst.go.jp) and Yuhei Takado 10 (takado.yuhei@qst.go.jp), and will be available upon reasonable request.

11

# 12 **Declaration of Competing Interest**

13 Hitoshi Shimada, Ming-Rong Zhang, and Makoto Higuchi hold patents on compounds

14 related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672).

15

# 16 Credit authorship contribution statement

Kenji Tagai, Yoko Ikoma: Conceptualization, Methodology, Formal analysis, Writing original draft. Hironobu Endo, Oriendrila Debnath, Chie Seki, Maiko Ono:
Conceptualization, Methodology. Kiwamu Matsuoka, Keisuke Takahata, Hitoshi
Shinotoh, Hideki Matsumoto, Masaki Oya, Kosei Hirata, Shin Kurose, Yasunori
Sano, Hitoshi Shimada: Collection of clinical data. Kazunori Kawamura, Ming-Rong
Zhang: Radioligand synthesis. Yuhei Takado, Makoto Higuchi: Conceptualization,
Writing - review & editing, Funding acquisition, Supervision

# 1 Acknowledgements

 $\mathbf{2}$ The authors thank all patients and their caregivers for participation in this study, as well as clinical research coordinators, PET and MRI operators, radiochemists, and research 3 ethics advisers at QST for their assistance with the current projects. We thank APRINOIA 4 Therapeutics for kindly sharing a precursor of <sup>18</sup>F-PM-PBB3. The authors acknowledge  $\mathbf{5}$ support with the recruitment of patients by Shunichiro Shinagawa at the Department of 6 Psychiatry, Jikei University School of Medicine; Shigeki Hirano at the Department of 7 Neurology, Chiba University; Taku Hatano, Yumiko Motoi, and Shinji Saiki at the 8 9 Department of Neurology, Juntendo University School of Medicine; Ikuko Aiba at the 10 Department of Neurology, National Hospital Organization Higashinagoya National Hospital; Yasushi Shiio and Tomonari Seki at the Department of Neurology, Tokyo 11 12Teishin Hospital; Hisaomi Suzuki at the National Hospital Organization Shimofusa Psychiatric Medical Center. 13

14

#### 15 Supplementary materials

16 Supplementary material associated with this article can be found in the online version.

17

#### 18 **References:**

19

Buee L, Bussiere T, Buee\_Scherrer V, Delacourte A, Hof PR. Tau protein isoforms,
 phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33(1):95–
 130.

23 2. Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, et al. Structure-based classification
of tauopathies. Nature. 2021;598(7880):359–63.

Arima K. Ultrastructural characteristics of tau filaments in tauopathies: immuno\_electron
microscopic demonstration of tau filaments in tauopathies. Neuropathology. 2006;26(5):475–83.

27 4. Delacourte A. Tauopathies: recent insights into old diseases. Folia Neuropathol.

1 2005;43(4):244-57.

 $\mathbf{2}$ Villemagne VL, Dore V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-beta 5. proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14(4):225-36. 3 4 Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez–Vieitez E, et al. Tau PET 6.  $\mathbf{5}$ imaging in neurodegenerative tauopathies\_still a challenge. Mol Psychiatry.  $2019;24_{(8)}:1112_{-34}$ . Barret O, Alagille D, Sanabria S, Comley RA, Weimer RM, Borroni E, et al. Kinetic Modeling 6 7. 7 of the Tau PET Tracer (18)F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects. 8 J Nucl Med. 2017;58(7):1124–31. 9 Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, et al. In vivo 8. 10 quantification of neurofibrillary tangles with [(18)F]MK=6240. Alzheimers Res Ther. 2018;10(1):74. 11 9. Kuwabara H, Comley RA, Borroni E, Honer M, Kitmiller K, Roberts J, et al. Evaluation of 12(18)F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain. | Nucl Med. 132018;59(12):1877-84. 14Mueller A, Bullich S, Barret O, Madonia J, Berndt M, Papin C, et al. Tau PET imaging with 10. 15(18)F–PI–2620 in Patients with Alzheimer Disease and Healthy Controls: A First–in–Humans Study. 16J Nucl Med. 2020;61(6):911–9. 17Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology 11. 18in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 192013;79(6):1094–108. 20Tagai K, Ono M, Kubota M, Kitamura S, Takahata K, Seki C, et al. High-Contrast In Vivo 12. 21Imaging of Tau Pathologies in Alzheimers and Non-Alzheimers Disease Tauopathies. Neuron. 222021;109(1):42-58 e8. 23Kimura Y, Endo H, Ichise M, Shimada H, Seki C, Ikoma Y, et al. A new method to quantify tau 13. 24pathologies with (11)C-PBB3 PET using reference tissue voxels extracted from brain cortical gray 25matter. EJNMMI Res. 2016;6(1):24. 2614. Endo H, Shimada H, Sahara N, Ono M, Koga S, Kitamura S, et al. In vivo binding of a tau 27imaging probe,  $\lceil (11) \rangle$  C<sub>1</sub>PBB3, in patients with progressive supranuclear palsy. Mov Disord. 282019;34(5):744-54. 2915. Shinotoh H, Shimada H, Kokubo Y, Tagai K, Niwa F, Kitamura S, et al. Tau imaging detects 30 distinctive distribution of tau pathology in ALS/PDC on the Kii Peninsula. Neurology. 312019;92(2):e136-e47. 32Takahata K, Kimura Y, Sahara N, Koga S, Shimada H, Ichise M, et al. PET-detectable tau 16. 33pathology correlates with long\_term neuropsychiatric outcomes in patients with traumatic brain 34injury. Brain. 2019;142(10): 3265-79. 3517. Southekal S, Devous MD, Sr., Kennedy I, Navitsky M, Lu M, Joshi AD, et al. Flortaucipir F 18 36 Quantitation Using Parametric Estimation of Reference Signal Intensity. J Nucl Med.

 $1 \quad 2018;59_{(6)}:944_{-51}.$ 

 $\mathbf{2}$ Zhang H, Wang M, Lu J, Bao W, Li L, Jiang J, et al. Parametric Estimation of Reference Signal 18. 3 Intensity for Semi–Quantification of Tau Deposition: A Flortaucipir and [(18)F]–APN–1607 Study. 4 Front Neurosci. 2021;15:598234.  $\mathbf{5}$ 19. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive 6 impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3): 303–8. 7 McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of 20. 8 Alzheimers disease: report of the NINCDS\_ADRDA Work Group under the auspices of Department of 9 Health and Human Services Task Force on Alzheimers Disease. Neurology. 1984;34(7):939–44. 10 21. Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical 11 diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 122017;32(6):853-64. 1322. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis 14of corticobasal degeneration. Neurology. 2013;80(5):496–503. 1523. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of 16revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 172011;134(Pt 9): 2456-77. 1824. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. 19Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-14. 20Klein A, Tourville J. 101 labeled brain images and a consistent human cortical labeling 25. 21protocol. Front Neurosci. 2012;6:171. 22Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for 26. 23characterizing longitudinal amyloid\_beta PET changes and evaluating amyloid\_modifying treatments 24with a cerebral white matter reference region. [Nucl Med. 2015;56(4); 560–6. 2527. Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of 26longitudinal beta\_amyloid change with 18F\_florbetapir PET and standardized uptake value ratios. [ 27Nucl Med. 2015;56(4):567–74. 2828. Baker SL, Harrison TM, Maass A, La Joie R, Jagust WJ. Effect of Off-Target Binding on (18)F-29Flortaucipir Variability in Healthy Controls Across the Life Span. | Nucl Med. 2019;60(10): 1444–51. 30 29. Moscoso A, Grothe MJ, Scholl M, Alzheimers Disease Neuroimaging I. Reduced 31[(18)F]flortaucipir retention in white matter hyperintensities compared to normal\_appearing white 32matter. Eur J Nucl Med Mol Imaging. 2021;48(7): 2283–94. 3330. Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, et al. Distribution patterns 34of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020;140(2):99-119. 35Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, et al. Pathological tau burden 31. 36 and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardsons

1	syndrome_Brain_2007:130/Pt 6.:1566_76				
2	32. Kouri N. Murray ME. Hassan A. Rademakers R. Uitti RI. Boeve BF. et al. Neuropathological				
3	features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome.				
4	Brain. $2011;134$ Pt $11$ ): $3264-75$ .				
<b>5</b>	33. Ling H, Kovacs GG, Vonsattel JP, Davey K, Mok KY, Hardy J, et al. Astrogliopathy predominates				
6	the earliest stage of corticobasal degeneration pathology. Brain. 2016;139(Pt 12): 3237–52.				
7	34. Shiozawa M, Fukutani Y, Sasaki K, Isaki K, Hamano T, Hirayama M, et al. Corticobasal				
8	degeneration: an autopsy case clinically diagnosed as progressive supranuclear palsy. Clin				
9	Neuropathol. 2000;19(4):192–9.				
10	35. Piao YS, Hayashi S, Wakabayashi K, Kakita A, Aida I, Yamada M, et al. Cerebellar cortical tau				
11	pathology in progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol.				
12	2002;103 <sub>(</sub> 5 <sub>)</sub> :469–74.				
13	36. Koga S, Josephs KA, Ogaki K, Labbe C, Uitti RJ, Graff–Radford N, et al. Cerebellar ataxia in				
14	progressive supranuclear palsy: An autopsy study of PSP_C. Mov Disord. 2016; $31(5)$ : 653–62.				
15					
16					
17					
18					
10					
19					
20					
21					
22					
23					
24					
95					
20					
26					
27					





Figure 1: Flowcharts of extracting reference tissues by developed algorithm on <sup>18</sup>F PM-PBB3 PET images.

4 The yellow-labeled regions show extracted references based on bimodal/monomodal
5 Gaussian fitting, respectively.

6 (A) A histogram obtained from a PSP-Richardson case, and the reference was extracted  $\overline{7}$ from the 1st Gaussian distribution based on bimodal fitting. (B) shows histograms obtained from a PSP-PGF case. The amplitude of the 1st peak was less than half of the 8 2nd peak on bimodal fitting (left), and the Dice coefficient was higher than the threshold 9 value (>0.939) on monomodal fitting (right). Hence, the reference was set based on 1011 monomodal fitting. (C) shows histograms obtained from an AD case. The amplitude of 12the 1st peak was less than half of the 2nd peak on bimodal fitting (left), whereas the Dice coefficient was lower than the threshold value (<0.939) on monomodal fitting (right). 1314Ultimately, the reference was set based on bimodal fitting.

1



3 Figure 2: Comparisons of characteristics of GM-ref and WM-ref generated using

# 4 histograms.

- 5 References generated by the histograms in representative cases of HCs and patients with
- 6 AD and PSP. All PET images were co-registered T1-weighted MR images; red labeled
- 7 regions demonstrate generated GM-ref (upper row); yellow labeled regions show WM-
- 8 ref (lower row).
- 9



1



(A, B) Scatter plots show SUVR values of Braak V/VI (A) and STN (B) in the case of
quantified by each reference. The color of each dot indicates the clinical profile: Black
circles; (HC), white squares; (MCI), black squares; (AD), blue circles; (PSP-Richardson)
and red circles; (PSP-other). Asterisks represent P < 0.05 by Mann-Whitney U test.</li>

8 (C) ROC curves estimated from each reference are shown for the following groups:

1	HCs vs MCI/AD (left) and PSP (right). Each color shows the type of references: black
2	(CB-ref), blue (GM-ref), and red (WM-ref).
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	







# Figure 5: Direct comparison of SUVRs quantified by CB-ref and GM-ref in HCs and PSP patients.

(A) SUVR parametric images quantified by CB-ref in the upper row and by GM-ref in
the lower row are shown. Tracer retention was increased and visualized in GM-ref
compared to CB-ref in areas with well-known PSP pathology such as basal ganglia
(white arrowheads) and motor cortex (yellow arrowheads). The asterisk image was
obtained from a neuropathologically confirmed PSP patient.
(B) The Scatterplot demonstrates a linear regression analysis. Blue circles, (PSPRichardson); red circles, (PSP with other clinical phenotypes). SUVR values are

12

11

estimated from STN VOI.





Figure 6: Direct comparison of SUVRs quantified by CB-ref and GM-ref in other
FTLD patients.

(A) SUVR parametric images quantified by CB-ref in upper row and by GM-ref in 4 lower row are shown. Tracer retention was increased and visualized in GM-ref  $\mathbf{5}$ compared to CB-ref in CBD, Non-AD CBS, PNFA and patients but remained almost 6 the same in BvFTD and PiD patients. Arrowheads indicate each target region: motor  $\overline{7}$ (yellow) and orbito (white) frontal cortices. Asterisked images were derived from 8 9 neuropathologically confirmed patients. (B) Comparison of SUVR values quantified by CB-ref and GM-ref n each target region. 10 Each target region was set at precentral cortex of CBD (magenta triangle), Non-AD 11 12CBS (magenta circle) and PNFA (magenta square) patients, and orbitofrontal cortex 13 of BvFTD (light blue circle) and PiD (light blue triangle).

	НС	AD	PSP
Demographics			
Number	40	23	40
Age	68.6 (5.7)	66.2 (10.0)	70.4 (6.4)
Gender (male/female)	25/15	11/12	22/18
MMSE	28.3 (1.5)	21.8 (3.7) *†	24.8 (4.6)*
PSPRS	N/A	N/A	38.1 (18.2)
Volumes of reference (cm <sup>3</sup> )			
CB-ref	62.8 (7.3)	65.3 (11.1)	60.4 (9.7)
GM-ref	124.6 (31.0)	52.5 (21.6) <sup>*†</sup>	95.8 (36.2)*
WM-ref	157.6 (28.1)	144.8 (26.9)	142.8 (29.4)*

# 1 Table 1: Demographics and characteristics of each reference

#### $\mathbf{2}$

3

HC, healthy control; AD, Alzheimer's disease; PSP, progressive supranuclear palsy;
MMSE, mini-mental state examination; PSPRS, progressive supranuclear palsy rating
scale; CB-ref, cerebellar reference; GM-ref, gray matter reference; WM-ref, white matter
reference

PSP patients consisted of 33 PSP-Richardson and seven PSP with other clinical
phenotypes: PSP with progressive gait freezing (PSP-PGF), predominant parkinsonism
(PSP-P), and predominant speech/ language disorder (PSP-SL).

11 Values are listed as mean  $\pm$  standard deviation.

12 \*, HC higher than AD and PSP, P < 0.05

13 <sup>†</sup>, PSP higher than AD, P < 0.05